ATE413180T1 - Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs - Google Patents

Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs

Info

Publication number
ATE413180T1
ATE413180T1 AT02715041T AT02715041T ATE413180T1 AT E413180 T1 ATE413180 T1 AT E413180T1 AT 02715041 T AT02715041 T AT 02715041T AT 02715041 T AT02715041 T AT 02715041T AT E413180 T1 ATE413180 T1 AT E413180T1
Authority
AT
Austria
Prior art keywords
breast cancer
methylation
modulating compounds
intraductal
treatment
Prior art date
Application number
AT02715041T
Other languages
English (en)
Inventor
David Hung
Original Assignee
Cytyc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytyc Corp filed Critical Cytyc Corp
Application granted granted Critical
Publication of ATE413180T1 publication Critical patent/ATE413180T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT02715041T 2001-03-30 2002-03-27 Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs ATE413180T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27976201P 2001-03-30 2001-03-30
US10/101,631 US20020142941A1 (en) 2001-03-30 2002-03-21 Intraductal treatment targeting methylated promoters in breast cancer

Publications (1)

Publication Number Publication Date
ATE413180T1 true ATE413180T1 (de) 2008-11-15

Family

ID=26798462

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02715041T ATE413180T1 (de) 2001-03-30 2002-03-27 Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs

Country Status (8)

Country Link
US (2) US20020142941A1 (de)
EP (1) EP1372671B1 (de)
JP (2) JP2004525151A (de)
AT (1) ATE413180T1 (de)
AU (1) AU2002247262B2 (de)
DE (1) DE60229727D1 (de)
ES (1) ES2314041T3 (de)
WO (1) WO2002078716A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE341345T1 (de) * 1999-06-11 2006-10-15 Cytyc Corp Flüssige gelformulierung zum detektieren von milchkanälen in der brust vor einer chirurgischen ablation des brustgewebes
EP2111385B1 (de) * 2007-02-06 2014-11-12 University Of Louisville Research Foundation, Inc. Substituierte Alkinderivate als Antikrebsmittel
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US20100239635A1 (en) 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
CN102292458A (zh) 2009-04-03 2011-12-21 A&T株式会社 大肠肿瘤的检测方法
WO2011031561A2 (en) * 2009-08-27 2011-03-17 Ensisheim Partners Llc Nucleic acid molecules and uses thereof
US20130059903A1 (en) * 2010-03-12 2013-03-07 The Johns Hopkins University Compositions and Methods for Characterizing Breast Cancer
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (de) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und -therapien
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3094072A1 (en) * 2018-03-15 2019-09-19 Atossa Therapeutics, Inc. In situ methods of inducing of immune response
CN111363819A (zh) * 2020-01-08 2020-07-03 武汉科技大学 一种利用ddPCR技术联合检测诊断乳腺癌的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5101072A (en) * 1989-09-06 1992-03-31 Yale University Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
US6255293B1 (en) * 1998-07-24 2001-07-03 Yeda Research And Development Co., Ltd. Prevention of metastasis with 5-aza-2′-deoxycytidine

Also Published As

Publication number Publication date
AU2002247262B2 (en) 2008-09-04
EP1372671B1 (de) 2008-11-05
JP2009096808A (ja) 2009-05-07
ES2314041T3 (es) 2009-03-16
WO2002078716A2 (en) 2002-10-10
JP2004525151A (ja) 2004-08-19
DE60229727D1 (de) 2008-12-18
US20050272685A1 (en) 2005-12-08
WO2002078716A3 (en) 2002-11-21
US20020142941A1 (en) 2002-10-03
EP1372671A2 (de) 2004-01-02

Similar Documents

Publication Publication Date Title
DE60229727D1 (de) Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
MX2023015236A (es) Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y sus usos para el tratamiento de cancer.
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DK1261367T3 (da) Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer
ATE323474T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
SI1472541T1 (sl) Prikazovalni agensi in postopek prikazovanja naaladase ali psma
EP1844077A4 (de) Dr5-antikörper und deren verwendung
PL360262A1 (pl) Kompozycje polimerycznych micelli
MA42999B1 (fr) Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë
HRPK20041072B3 (hr) Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
BR0010702A (pt) Novas quinonas como terapias de doenças
FR2869540B1 (fr) Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers
AU3392901A (en) Proteins
CY1110043T1 (el) 2-αμινοβενζουλ παραγωγα
EP1694364A4 (de) System zur behandlung und prävention von brustkrebs
PL369305A1 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
DE50211672D1 (de) Urokinase-inhibitoren
ATE348183T1 (de) Zusammensetzungen und verfahren zur intraductalen gentherapie
ATE298328T1 (de) Taxan-derivate für die behandlung von krebs
ATE252896T1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties